Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596245 · ClinicalTrials.gov registry record · Phase 1
Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00596245 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 42 participants.
The verdict
NCT00596245, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is an open-label, parallel group, single-center study. The study design consists of a screening and a treatment period. A total of 42 (approximately 21 of each sex) non-smoking healthy volunteers aged 18 - 35.
Interventions
- DRUG MT400
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00596245
The ClinicalTrials.gov registry entry for NCT00596245 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MT400 is the first listed.
NCT00596245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00596245 about?
NCT00596245 is a clinical study titled "Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets". This is an open-label, parallel group, single-center study. The study design consists of a screening and a treatment period. A total of 42 (approximately 21 of each sex) non-smoking healthy volunteers aged 18 - 35.
What is the current status of trial NCT00596245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2007-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00596245?
The interventions under investigation include: MT400 (DRUG).
Who is sponsoring clinical trial NCT00596245?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.